Royalty Pharma PLC $RPRX Shares Purchased by Handelsbanken Fonder AB

Handelsbanken Fonder AB boosted its stake in Royalty Pharma PLC (NASDAQ:RPRX) by 21.6% in the 4th quarter, Holdings Channel reports. The firm owned 315,686 shares of the biopharmaceutical company’s stock after buying an additional 56,061 shares during the quarter. Handelsbanken Fonder AB’s holdings in Royalty Pharma were worth $12,198,000 as of its most recent SEC filing.

Other large investors have also recently added to or reduced their stakes in the company. Mirae Asset Global Investments Co. Ltd. boosted its position in Royalty Pharma by 28.5% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 140,131 shares of the biopharmaceutical company’s stock valued at $4,944,000 after buying an additional 31,045 shares during the last quarter. Regal Partners Ltd increased its position in shares of Royalty Pharma by 6.7% during the third quarter. Regal Partners Ltd now owns 1,435,126 shares of the biopharmaceutical company’s stock worth $50,631,000 after acquiring an additional 89,930 shares during the last quarter. Nordea Investment Management AB increased its position in shares of Royalty Pharma by 4.7% during the fourth quarter. Nordea Investment Management AB now owns 812,663 shares of the biopharmaceutical company’s stock worth $31,604,000 after acquiring an additional 36,664 shares during the last quarter. Sumitomo Mitsui Trust Group Inc. lifted its stake in shares of Royalty Pharma by 15.1% in the fourth quarter. Sumitomo Mitsui Trust Group Inc. now owns 1,268,044 shares of the biopharmaceutical company’s stock worth $48,997,000 after acquiring an additional 166,403 shares in the last quarter. Finally, Alps Advisors Inc. acquired a new position in shares of Royalty Pharma in the third quarter worth about $19,514,000. 54.35% of the stock is currently owned by institutional investors and hedge funds.

Royalty Pharma Stock Performance

Shares of RPRX stock opened at $53.55 on Friday. The company has a debt-to-equity ratio of 0.86, a quick ratio of 2.66 and a current ratio of 2.66. Royalty Pharma PLC has a one year low of $32.15 and a one year high of $53.59. The company’s 50-day simple moving average is $48.87 and its 200-day simple moving average is $43.84. The stock has a market capitalization of $30.84 billion, a price-to-earnings ratio of 36.43, a PEG ratio of 1.46 and a beta of 0.40.

Royalty Pharma (NASDAQ:RPRX) last issued its quarterly earnings results on Wednesday, May 6th. The biopharmaceutical company reported $1.30 EPS for the quarter, topping the consensus estimate of $1.22 by $0.08. Royalty Pharma had a net margin of 33.88% and a return on equity of 29.25%. The business had revenue of $631.00 million for the quarter, compared to analysts’ expectations of $881.69 million. Equities analysts anticipate that Royalty Pharma PLC will post 5.05 earnings per share for the current fiscal year.

Royalty Pharma Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Wednesday, June 10th. Stockholders of record on Friday, May 15th will be given a dividend of $0.235 per share. The ex-dividend date of this dividend is Friday, May 15th. This represents a $0.94 annualized dividend and a dividend yield of 1.8%. Royalty Pharma’s dividend payout ratio (DPR) is presently 63.95%.

Insider Transactions at Royalty Pharma

In other news, EVP Marshall Urist sold 13,684 shares of the stock in a transaction dated Thursday, May 14th. The shares were sold at an average price of $53.06, for a total transaction of $726,073.04. Following the transaction, the executive vice president owned 31,881 shares of the company’s stock, valued at approximately $1,691,605.86. This trade represents a 30.03% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Terrance P. Coyne sold 34,791 shares of the stock in a transaction dated Tuesday, April 28th. The stock was sold at an average price of $49.78, for a total transaction of $1,731,895.98. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders have sold 169,577 shares of company stock valued at $8,234,191. Insiders own 18.84% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms recently commented on RPRX. Weiss Ratings cut Royalty Pharma from a “buy (b)” rating to a “buy (b-)” rating in a research note on Friday, May 15th. Citigroup boosted their price target on Royalty Pharma from $50.00 to $66.00 and gave the stock a “buy” rating in a research note on Thursday, May 7th. Morgan Stanley boosted their price target on Royalty Pharma from $61.00 to $63.00 and gave the stock an “overweight” rating in a research note on Friday, April 10th. Wall Street Zen upgraded Royalty Pharma from a “buy” rating to a “strong-buy” rating in a research note on Saturday, May 9th. Finally, JPMorgan Chase & Co. boosted their price target on Royalty Pharma from $50.00 to $58.00 and gave the stock an “overweight” rating in a research note on Thursday, May 7th. Seven analysts have rated the stock with a Buy rating, According to data from MarketBeat, Royalty Pharma has an average rating of “Buy” and a consensus target price of $53.71.

About Royalty Pharma

Royalty Pharma plc is a specialty finance company that acquires biopharmaceutical royalty interests and provides non-dilutive financing to drug developers and rights holders. The firm purchases future royalty streams, milestone-contingent payments and other revenue rights linked to approved and late-stage pharmaceutical and biotechnology products. By paying upfront consideration for these rights, Royalty Pharma seeks to generate long-term cash flows tied to the commercial performance of a diversified portfolio of medicines.

The company’s transaction structures include outright royalty purchases, structured financings and milestone arrangements tailored to the needs of innovator companies, academic institutions and investors.